GAIN THERAPEUTICS INC

NASDAQ: GANX (Gain Therapeutics, Inc.)

Kemas kini terakhir: semalam, 1:43PM

0.975

-0.07 (-6.25%)

Penutupan Terdahulu 1.04
Jumlah Dagangan 521,050
Harga / Buku (P/B) 4.54
Julat 52 Minggu
0.940 (-3%) — 4.34 (345%)
EPS Cair (TTM) -0.830
Jumlah Hutang/Ekuiti (D/E MRQ) 10.50%
Nisbah Semasa (MRQ) 2.22
Aliran Tunai Operasi (OCF TTM) -19.11 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -10.84 M
Pulangan Atas Aset (ROA TTM) -97.10%
Pulangan Atas Ekuiti (ROE TTM) -290.21%

AISkor Stockmoo

-3.0
Nilai 30% -2.1
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info
Masa 30% -4.1
Daripada analisis teknikal AI kami terhadap carta. info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Corak Lilin info NA
Aliran bagi Tempoh Pegangan Anda info NA
Sentimen 20% 0.0
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Berita info NA
Wang Pintar 20% -1.4
Aktiviti Orang Dalam info NA
Institusi bersih -0.52% daripada saham dalam pemfailan 13F terkini: 23 pemegang menambah, 18 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +39.2% dari 31 Aug hingga 30 Oct 2026, 5.5 hari untuk tutup (FINRA). info
Keadaan pasaran dan sektor lemah.
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Tidak dikira dalam skor
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menurun. info
Skor Akhir -2.99

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Gain Therapeutics, Inc. Bercampur Bercampur

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
GANX - - - 4.54
TRML 1 B - - 4.76
TECH - 0.44% - 5.28
MLTX - - - 2.79
VKTX - - - 6.33
VSTM - - - 76.50

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 3.78%
% Dimiliki oleh Institusi 8.14%

Pemilikan

Nama Tarikh Syer Dipegang
Cambridge Investment Research Advisors, Inc. 30 Sep 2026 566,645
Dme Capital Management, Lp 30 Jun 2026 566,130
Cresset Asset Management, Llc 30 Jun 2026 160,000

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 20.51%

Kedudukan Pemegang Saham
Bertambah 23 865,600
Berkurang 18 1,105,450
Baharu 11 427,858
Dijual habis 6 422,295

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 3,891,227 5.5
15 Oct 2026 3,191,453 6.5
30 Sep 2026 3,056,188 5.9
15 Sep 2026 2,887,151 8.9
31 Aug 2026 2,795,819 7.7
14 Aug 2026 2,952,391 4.9

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

1 Positif 0 Negatif 2 Neutral
Tarikh Jenis Butiran
16 Nov 2026 Yahoo Finance Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
10 Nov 2026 Yahoo Finance Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
BETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the…
05 Nov 2026 Yahoo Finance Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two…
08 Oct 2026 Yahoo Finance Gain Therapeutics to Attend the 2026 Maxim Growth Summit
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the…
01 Oct 2026 Yahoo Finance Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants with both high and low baseline levels of GluSph…
29 Sep 2026 Yahoo Finance Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at…
17 Sep 2026 Yahoo Finance Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President…
25 Aug 2026 Yahoo Finance Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President…

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda